Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 15:39
Please select the service you want to use:
Smartlinks | Columbus McKinnon Corporation | News | Finance | Security Markets | Security Markets | Company News | Top Company News | Corporate Debt | Financial Services | Investment Services | Securities Issuers | Lifting and Handling Equipment Manufacturers | Frankfurt Stock Exchange | Berlin Stock Exchange | Stuttgart Stock Exchange | NYSE American | NYSE ARCA Equities | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact